Cover Image
市場調查報告書

肺纖維化:開發平台分析

Pulmonary Fibrosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200483
出版日期 內容資訊 英文 377 Pages
訂單完成後即時交付
價格
Back to Top
肺纖維化:開發平台分析 Pulmonary Fibrosis - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 377 Pages
簡介

肺纖維化,由於肺的細胞受損傷而發生。由於類肉瘤病和韋格納肉芽腫的慢性發炎性疾病,及感染疾病,環境要素 (石棉,桂樹土,暴露於特定氣體),暴露於電離放射線等各種情形發病。症候有呼吸急促、乾咳、疲勞感、肌肉痛、關節痛等。

本報告提供肺纖維化的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關,開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

肺纖維化概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

肺纖維化:企業開發中的治療藥

肺纖維化:大學/機關研究中的治療藥

肺纖維化:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

肺纖維化:企業開發中的產品

肺纖維化:大學/機關研究中的產品

肺纖維化的治療藥開發作的企業

  • AdAlta Pty Ltd.
  • Advinus Therapeutics Ltd.
  • Aeolus Pharmaceuticals, Inc.
  • Afferent Pharmaceuticals, Inc.
  • AnaMar AB
  • Angion Biomedica Corp.
  • Antitope Limited
  • aTyr Pharma, Inc.
  • Biogen, Inc.
  • Bioneer Corporation
  • BiOrion Technologies B.V.
  • Bristol-Myers Squibb Company
  • Carolus Therapeutics, Inc.
  • Celgene Corporation
  • Chong Kun Dang Pharmaceutical Corp.
  • Clanotech AB
  • Compugen Ltd.
  • Cynata Therapeutics Limited
  • Diffusion Pharmaceuticals Inc.
  • Digna Biotech, S.L.
  • Elsalys Biotech SAS
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Galapagos NV
  • Galectin Therapeutics, Inc.
  • GenKyoTex S.A.
  • GlaxoSmithKline Plc
  • Global Blood Therapeutics, Inc.
  • HanAll Biopharma Co., Ltd.
  • HEC Pharm Co., Ltd.
  • Histocell S.L.
  • Hydra Biosciences, Inc.
  • iBio, Inc.
  • Inventiva
  • Isarna Therapeutics GmbH
  • Kadmon Corporation, LLC
  • Kasiak Research Private Limited
  • KineMed, Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Lpath, Inc.
  • miRagen Therapeutics, Inc.
  • Moerae Matrix, Inc.
  • MorphoSys AG
  • NicOx S.A.
  • Novartis AG
  • Pacific Therapeutics Ltd.
  • Pharmaxis Limited
  • Pharmicell Co., Ltd.
  • Pluristem Therapeutics Inc.
  • Progenra, Inc.
  • Promedior, Inc.
  • ProMetic Life Sciences Inc.
  • Pulmatrix, Inc.
  • RedHill Biopharma Ltd.
  • Respira Therapeutics, Inc.
  • Rhizen Pharmaceuticals S.A.
  • Ribomic Inc.
  • Saje Pharma, LLC
  • Sanofi
  • SciFluor Life Sciences, LLC
  • Symic Biomedical, Inc.
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • Teva Pharmaceutical Industries Limited
  • Therabron Therapeutics, Inc.
  • Vericel Corporation
  • Yuhan Corporation

肺纖維化:治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

肺纖維化:最近的開發平台趨勢

肺纖維化:暫停中的計劃

肺纖維化:開發中止的產品

肺纖維化:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8475IDB

Summary

Global Markets Direct's, 'Pulmonary Fibrosis - Pipeline Review, H2 2016', provides an overview of the Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
  • The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Pulmonary Fibrosis Overview
  • Therapeutics Development
  • Pulmonary Fibrosis - Therapeutics under Development by Companies
  • Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Pulmonary Fibrosis - Pipeline Products Glance
  • Pulmonary Fibrosis - Products under Development by Companies
  • Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
  • Pulmonary Fibrosis - Companies Involved in Therapeutics Development
  • Pulmonary Fibrosis - Therapeutics Assessment
  • Drug Profiles
  • Pulmonary Fibrosis - Dormant Projects
  • Pulmonary Fibrosis - Discontinued Products
  • Pulmonary Fibrosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Pulmonary Fibrosis, H2 2016
  • Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2016
  • Pulmonary Fibrosis - Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016
  • Pulmonary Fibrosis - Pipeline by Apellis Pharmaceuticals Inc, H2 2016
  • Pulmonary Fibrosis - Pipeline by Asahi Kasei Pharma Corp., H2 2016
  • Pulmonary Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Biogen Inc, H2 2016
  • Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H2 2016
  • Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016
  • Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2016
  • Pulmonary Fibrosis - Pipeline by Chrysalis Pharma SAS, H2 2016
  • Pulmonary Fibrosis - Pipeline by Clanotech AB, H2 2016
  • Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2016
  • Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H2 2016
  • Pulmonary Fibrosis - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H2 2016
  • Pulmonary Fibrosis - Pipeline by Elsalys Biotech SAS, H2 2016
  • Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by FibroStatin SL, H2 2016
  • Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2016
  • Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2016
  • Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by GNI Group Ltd., H2 2016
  • Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016
  • Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2016
  • Pulmonary Fibrosis - Pipeline by Hydra Biosciences, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Immunomet Therapeutics, Inc. , H2 2016
  • Pulmonary Fibrosis - Pipeline by Inventiva, H2 2016
  • Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016
  • Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H2 2016
  • Pulmonary Fibrosis - Pipeline by KineMed, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Pulmonary Fibrosis - Pipeline by Lpath, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Lung Therapeutics, Inc, H2 2016
  • Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2016
  • Pulmonary Fibrosis - Pipeline by NicOx S.A., H2 2016
  • Pulmonary Fibrosis - Pipeline by Nitto Denko Corporation, H2 2016
  • Pulmonary Fibrosis - Pipeline by Novartis AG, H2 2016
  • Pulmonary Fibrosis - Pipeline by Nuevolution AB, H2 2016
  • Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2016
  • Pulmonary Fibrosis - Pipeline by Pharmicell Co., Ltd., H2 2016
  • Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H2 2016
  • Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
  • Pulmonary Fibrosis - Pipeline by Ribomic Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Saje Pharma, LLC, H2 2016
  • Pulmonary Fibrosis - Pipeline by Sanofi, H2 2016
  • Pulmonary Fibrosis - Pipeline by Sirnaomics, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by SPR Biosciences LLC, H2 2016
  • Pulmonary Fibrosis - Pipeline by Symic Biomedical, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
  • Pulmonary Fibrosis - Pipeline by Terpenoid Therapeutics, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Pulmonary Fibrosis - Pipeline by Therabron Therapeutics, Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Vault Pharma Inc., H2 2016
  • Pulmonary Fibrosis - Pipeline by Vericel Corporation, H2 2016
  • Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H2 2016
  • Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pulmonary Fibrosis - Dormant Projects, H2 2016
  • Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2016
  • Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2016
  • Pulmonary Fibrosis - Dormant Projects (Contd..3), H2 2016
  • Pulmonary Fibrosis - Dormant Projects (Contd..4), H2 2016
  • Pulmonary Fibrosis - Dormant Projects (Contd..5), H2 2016
  • Pulmonary Fibrosis - Dormant Projects (Contd..6), H2 2016
  • Pulmonary Fibrosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Pulmonary Fibrosis, H2 2016
  • Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top